According to the univariate analysis (Table 2), in the younger group, the 5-year disease-free survival (DFS) was slightly higher in the patients with adju- vant chemotherapy (5-year DFS: 62.1% vs. 33.3%, p = 0.095), and the 5-year overall survival (OS) was sig-<br>nificantly higher (5-year OS: 77.9% vs. 50.0%, p = 0.026) (Fig. 1).<br>In the older group, the 5-year OS in patients re- ceiving chemotherapy was 64.6 %, which was signifi- cantly higher than in patients without adjuvant chem- otherapy (40.9%, p = 0.013); however, the 5-year DFS of the older group did nott reach statistical sig- nificance. (55.6% vs. 49.8% of the control group, p = 0.668) (Fig. 1).<br>The rate of adverse events for patients with intra- venous chemotherapy or oral chemotherapy is listed in Table 3, according to different age groups. Older pa- tients with oral chemotherapy did not report more ad- verse events than the younger group. However, among the patients receiving intravenous chemotherapy, the frequency of neutropenia (15.7% vs. 8.4%; p = 0.038) and anemia (21.1% vs. 8.5%; p = 0.003) was signifi- cantly higher in the older group.
正在翻譯中..
